This week's top news includes an industry leader Q&A, an IBD antibody and a drive to improve sustainability in pharma...

? Developing the EU’s first intestinal microbiota-based biologic

Dr Olaia Aurtenetxe , Head of Clinical Research at Mikrobiomik , reveals study data demonstrating why MBK-01, an investigational drug based on faecal microbiota transplantation, presents a promising alternative to the current standard of care for Clostridioides difficile infections (CDI), potentially reducing antibiotic use and antimicrobial resistance.

Since 2018, biotech company Mikrobiomik has been researching, development and producing innovative biological medicines based on the human microbiome. We are proud to be the first company planning to market MBK-01, the EU’s first biologic based on intestinal microbiota, full spectrum purified intestinal microbiota (FSPIM), in the form of lyophilised capsules for oral administration.

Find out more ICD-01 trial results, efficacy and safety outcomes of MBK-01 and further findings for MBK-01 here.

? EFPIA sets out targets for pharma environmental sustainability

To drive environmental sustainability in pharma, EFPIA - European Federation of Pharmaceutical Industries and Associations strives “to go beyond compliance on the targets set within the various EU legislative requirements as part of the EU Green Deal initiatives under the Zero Pollution, Circular Economy and Climate Action plans”.

Read more about how they will achieve their targets of carbon reduction, environmental sustainability, advancing circularity and pharmaceuticals in the environment, here.

? Modifier gene therapy – clinical development and manufacturing considerations

Dr Arun Upadhyay , Chief Scientific Officer and Head of Research & Development at Ocugen , discusses the company’s promising modifier gene therapy candidates for ophthalmic disorders.

Find out more about the top three challenges associated with gene therapy manufacturing, the impact of new technology and treatment outcomes and options, here.

? AbbVie to advance TL1A antibody for IBD

AbbVie and FutureGen Laboratories have made a license agreement whereby AbbVie will develop, manufacture and commercialise a next generation TL1A antibody for inflammatory bowel disease (IBD).

While AbbVie is set to advance the monoclonal antibody through development and beyond, the treatment is currently in preclinical development.

Read more here.

European Pharmaceutical Review is an essential resource for students, researchers and industry professionals looking for the latest industry insights and innovations.

>> Sign up for free now <<